Background The clinical impact of salvage surgery after chemotherapy on cancer survival of patients with metastatic urothelial carcinoma is controversial. We aimed to verify the clinical role of salvage surgery by analyzing the long-term outcome in patients with urothelial carcinoma treated by chemotherapy. Methods Between 2003 and 2010 at a single institution, 31 of 47 patients (66%) with metastatic urothelial carcinoma showed objective responses (CR in 4, PR in 27) after multiple courses of cisplatin/gemcitabine/paclitaxel-based chemotherapy, and a cohort of patients with partial response (PR) were retrospectively enrolled. Twelve (10 male and 2 female, median age 64.0 years) of 27 patients with PR underwent salvage surgeries after the chemotherapy: metastatectomy of residual lesions (10 retroperitoneal lymph nodes, 2 lung), and 6 radical surgeries for primary lesions as well. Progression-free survival and overall patient survival rates were analyzed retrospectively and compared with those of patients without salvage surgery. Results All 12 patients achieved surgical CR. Pathological findings of metastatic lesions showed viable cancer cells in 3 patients. In univariate analysis, sole salvage surgery affected overall survival in 27 patients with PR to the chemotherapy (P = 0.0037). Progression-free survival and overall survival rates in patients with salvage surgery were better than those in 15 PR patients without the surgery (39.8 vs. 0%, and 71.6 vs. 12.1% at 3 years, P = 0.01032 and 0.01048; log-rank test). Conclusions Salvage surgery for patients with residual tumor who achieve partial response to chemotherapy could have a possible impact on cancer survival.
Introduction
Modern cisplatin-based combination systemic chemotherapies for metastatic urothelial cancer have shown overall response rates of approximately 50-70% with median survival of about 13 months [1] [2] [3] [4] [5] . Of these chemotherapies, methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) have been the standard regimens for initially unresectable or metastatic urothelial cancer. Recently, the combination of gemcitabine and cisplatin (GC) has become a new standard treatment in metastatic urothelial cancer in Europe and North America, based on randomized trials showing similar survival but a more favorable toxicity profile for GC compared to MVAC [5] .
Although chemotherapy can achieve relatively high response rates in patients with metastatic urothelial cancer, fewer patients, even responders, can survive long-term on chemotherapy alone [6] . As part of a multidisciplinary approach, salvage surgery for residual metastatic masses after chemotherapy may improve prognoses of patients with metastatic urothelial cancer. Cowles et al. [7] , writing on the concept of surgical treatment for metastatic urothelial cancer, reported a median 5-year survival rate for six patients following thoracotomy for solitary pulmonary metastatic lesion. Due to the promising responses to chemotherapy, the therapeutic concept of surgery for metastatic urothelial cancer has been addressed again, a decade after the initial reports [8] [9] [10] [11] [12] [13] [14] . These reports support the therapeutic approach by surgical resection of metastatic lesion in patients with metastatic urothelial cancer. In addition, most tumor relapses after an initial response to systemic chemotherapy occur at prior sites of disease, which provides a possible rationale for salvage surgery of these residual masses [15] . Cisplatin/gemcitabine-based chemotherapy allows salvage surgery immediately following treatment due to its mild toxicity. However, the clinical impact of salvage surgery on survival benefit in responders to chemotherapy is still controversial. In this study, we verify the clinical role of salvage surgery by analyzing long-term outcome in patients with metastatic urothelial cancer treated by GC-based chemotherapy, focusing especially on a cohort of patients with partial response (PR), at a single institution.
Patients and methods
Between 2003 and 2010, 47 patients with metastatic urothelial cancer (34 male and 13 female, median age 64.2 years) were treated by systemic gemcitabine/cisplatin/ paclitaxel-based (GCP) chemotherapy [16] : gemcitabine 1000 mg/m 2 plus paclitaxel 80 mg/m 2 on days 1 and 8 and cisplatin 70 mg/m 2 on day 1 as GCP therapy (1-8 courses; median 3 courses) at our hospital with the approval of our Institutional Cancer Board. Seven patients were treated without paclitaxel, and two were treated without gemcitabine, due to drug allergy. All patients had distant metastases [visceral metastases or distant lymph node (LN) metastasis] and 19 had simultaneous advanced primary lesions. Fourteen patients received MVAC as prior chemotherapy before the GCP therapy. Thirty-one of the 47 patients (66%) showed objective responses by RECIST criteria [complete response (CR) in 4, PR in 27] after multiple courses of the chemotherapies.
In this study, we focused on and analyzed the cohort of patients with PR to the chemotherapy. Twelve of 27 patients with PR underwent salvage surgeries after chemotherapy (10 male and 2 female, median age 64.0 years). These patients underwent salvage surgery for residual lesions (10 retroperitoneal LNs, 2 lung). All six patients with simultaneous primary lesions underwent radical surgeries for primary lesions as well. Resections of metastatic urothelial cancer to render patients free of disease were regarded as salvage surgery; resections only for the purpose of symptom palliation were not.
Salvage surgery was generally considered in situations where patients had residual visceral metastases in a solitary organ with a small number of lesions and/or residual distant LN metastases after good response (PR) to the chemotherapies and good performance status (PS), although we did not have strict prospective criteria. All therapeutic decisions were left to the discretion of our department on the basis of individual clinical features and patient request for aggressive treatment.
Patient progression-free survival and overall survival rates were analyzed retrospectively. Survival was measured from the time of initiation of chemotherapy until death or the last follow-up. Clinical features were examined by univariate analysis for their association with survival. Variables considered were sex (male or female), age (B65 years or [65 years), primary site (bladder alone or other), radical resection of primary lesion (yes or no), number of metastatic organs (single or multiple), LN metastasis (yes or no), lung metastasis (yes or no), presence of liver or bone metastasis (yes or no), and salvage surgery (yes or no). Survival curves were estimated by the KaplanMeier method and survival distributions were compared by the log-rank test; P \ 0.05 was considered significant.
Results

Patients with PR to chemotherapy
A summary of the characteristics of the 27 patients with PR to the chemotherapies is shown in Table 1 . Eighteen patients had metastases at diagnosis of urothelial cancer, while metastases developed in 9 after the primary site had been treated surgically (radical surgery in 7; transurethral resection in 2). Patients received 3-9 courses of GCP therapy. Thirteen of the PR patients died of cancer and the remaining 14 survive. The overall and cause-specific 
Patients with salvage surgery
Twelve patients underwent salvage surgery after chemotherapy; their details are shown in Table 2 . Median age was 64.0 years old (range 41-73). The primary tumor site was the bladder in 4 patients and upper urinary tract in 8.
Five had single metastatic lesions and seven had multiple lesions. Nine (75%) patients with salvage surgery underwent adjuvant chemotherapy (2-3 courses of GCP chemotherapy). As for pathological findings in the salvage surgical specimens of metastatic lesions, viable cancer cells were recognized in 3 patients (1 in lung, and 2 in LN) whereas necrotic tissues were confirmed in the other 9.
Univariate analysis
Although gender, primary site, resection of primary site, number of metastatic organs, and metastatic site did not affect progression-free survival, salvage surgery and age did. As for overall/cause-specific survival, sole salvage surgery affected it strongly (P = 0.0037) ( Table 3 ). Figure 1a shows Kaplan-Meier progression-free survival curves with or without salvage surgery. Progressionfree survival rates at 2 and 3 years in patients with salvage surgery were 63.6 and 39.8%, respectively, and significantly longer than those in patients without salvage surgery (7.3% at 2 years, P = 0.01032). Figure 1b shows KaplanMeier overall/cause-specific survival curves with or without salvage surgery. The 3-and 5-year survival rates in patients with salvage surgery were both 71.6% and significantly longer than those in patients without salvage surgery (12.1%, P = 0.01048).
Discussion
Recently several authors have reported on the benefits of surgical resection of metastatic sites during a multidisciplinary approach for metastatic urothelial cancer [8] [9] [10] [11] [12] [13] [14] . Dodd et al. [8] reported that a 5-year overall survival rate of 33% was achieved in 50 patients with a major response to initial chemotherapy. In an updated series from the institute, 58% of patients who underwent post-chemotherapy surgery survived from 9 months to 5 years, while one of 12 patients (8%) who refused surgery remained alive [10] . They concluded that chemotherapy plus surgical resection of residual cancer to attain a complete response is critical for long-term survival in selected patients who would otherwise die of recurrent disease. The authors also described in their data that only one-third of the patients were deemed to be candidates for post-chemotherapy surgery, and, of these, about one-third survived [15] , meaning that post-chemotherapy surgery could save about 1 or 2 out of every 10 patients treated. Our results show that one quarter of patients with metastatic urothelial cancer were candidates for salvage surgery, and are similar to or relatively less than the rates described above. In our study, an influence on the results of bias by patient selection for salvage surgery should be considered. The patients who underwent salvage surgery might be a cohort of relatively low risk of recurrence compared to the patients who could not undergo surgery. No visceral metastasis except lung was treated by salvage surgery, and a high proportion (10/ 12) of patients with salvage surgery had retroperitoneal lymph node swelling alone. The difference in patients' backgrounds might affect the outcome even though statistical analysis in our small study could not reveal it. However, even considering the selection bias, the survival benefits for patients with salvage surgery were so apparent in our series that we regard salvage surgery as a potent method and important addition to a multidisciplinary approach to metastatic urothelial cancer.
The pathological findings in our surgical specimens showed a higher incidence (9 of 12 patients) of non-viable cancer cells than in prior reports: 33% in the Memorial Sloan-Kettering Cancer Center [10] and 18% in the German Group [14] . Our patients were treated by GCP chemotherapy, which differs from prior reports where MVAC therapy was mainly used. In addition, four clinical CR patients survived without recurrence. The high rate of pathological CR might be a reason for the high rate of survival in our series. On the other hand, the pathological findings may lead to a speculation that the patients who underwent salvage surgery have a bias towards relatively low risk of recurrence compared to the patients who could not undergo salvage surgery. Although these speculations may imply that salvage surgery for residual mass could be over-treatment for patients with only scarring in the specimen, we believe, as other investigators have pointed out [10, 17] , that salvage surgery is still worthwhile; negative pathology could also mean that residual nests of microscopic tumors were simply not detected in a large fibrotic specimen. On the other hand, surgery for metastatic sites where clinical CR was achieved by GCP therapy is still controversial, although the primary site should be removed even if showing clinical CR. The main issue is to identify patients most likely to benefit from salvage surgery [17] . Surgical resection has to be technically feasible and the number of metastatic foci limited. Salvage surgery should be curative. Otto et al. [19] reported on 70 patients undergoing resection of metastatic lesions with palliative intent after proving refractory to MVAC chemotherapy. While symptomatic patients experienced at least some relief, asymptomatic patients showed no beneficial palliative effects. Surgery with palliative intent is not beneficial and patients who failed to respond to chemotherapy did not survive in prior reports. The response to systemic chemotherapy is therefore important for survival for patients treated by a multidisciplinary approach. Although our study is small and retrospective, salvage surgery should only be offered to patients with a major response to chemotherapy where complete resection of all detectable masses seems feasible. In addition, since post-chemotherapy radiographs and scans are still unable to distinguish patients who have no evidence of residual pathological disease from those who do, it seems reasonable to consider salvage surgery in patients with a major response to chemotherapy. In our small number of patients with complete response to GCP therapy, long progressionfree survival rates were obtained without additional surgery. Surgery for metastatic sites remains controversial.
As for objective sites in salvage surgery, as Herr et al. described [18] , limited nodal or a solitary visceral or lung lesion is most likely to benefit from surgical resection. Patients with multiple liver metastases or metastases involving more than one visceral site or abdominal organ or bone metastases, especially involving the pelvis or axial skeleton, might not be candidates for salvage surgery even if they show a major response to chemotherapy, since prognoses in such patients were poor in prior reports. However, positron emission tomography (PET) scans may help to identify residual viable cancer, providing an indication for salvage surgery at a sole residual site in such patients in future. Finally, patient motivation and stamina for aggressive treatment may be the most important factors for salvage surgery.
Conclusions
Salvage surgery for patients with residual tumor who achieve partial response to chemotherapy could have a possible impact on cancer survival.
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